CRISPR Therapeutics AG (CRSP)
Pre-Market:
| Previous Close | 55.53 |
| Open | 54.30 |
| Bid | 53.24 x 300 |
| Ask | 53.32 x 500 |
| Day's Range | 52.62 - 54.50 |
| 52 Week Range | 37.55 - 91.10 |
| Volume | |
| Avg. Volume | 1,695,029 |
| Market Cap | 4.523B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.94 |
| Earnings Date | May 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 85.88 |
ZacksCRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 12.27% and 93.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireCRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
-More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected- -Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70 respectively, across multiple indications- -Clinical trials ongoing for in vivo gene editing product candidates, CTX310™ and CTX320™ targeting ANGPTL3 and Lp(a), respectively- -Expands pipeline with new preclinical programs utilizing lipid nanopar
- GlobeNewswire
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
- ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma - - Expands pipeline with new pre-clinical programs utilizing LNP mediated delivery to the liver for refractory hypertension targeting angiotensinogen (AGT) and acute hepatic porphyria (AHP) targeting 5’-aminolevulinate synthase 1 (ALAS1) - - CTX340™, targeting AGT in the liver, achieved durable editing of AGT and sust
